Share

EORTC Presentations at ESMO 2016 Congress in Copenhagen

EORTC investigators will present the results of their cancer research at ESMO 2016 Congress, 7 – 11 October 2016 in Copenhagen.

Presidential Symposium

Title: Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial

Details: ESMO 2016 Comgress, 08.10.2016, 16:30 – 18:00, Copenhagen

Abstract: 3070

Authors: Alexander MM Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A Ascierto, Jon M Richards, Céleste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S Weber, Corina Taitt, Veerle de Pril, Gaetan de Schaetzen, Stefan Suciu, Alessandro Testori

Poster Discussion session

Title: Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: investigating innate immunity as a tumor suppressor in breast cancer

Details: ESMO 2016 Congress, 10.10.2016, 13:00 – 14:00, Hall E

Abstract: 3615

Authors: Nathan Touati, Konstantinos Tryfonidis, Franco Caramia,  Hervé Bonnefoi,  David Cameron,  Leen Slaets,  Belinda S Parker, Sherene Loi


Title: Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis

Details: ESMO 2016 Congress, 10.10.2016, 13:00 – 14:00, Hall E

Abstract: 2355

Authors: Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Boccone P, Steeghs N, Safwat A, Katz D,  Duffaud F, Sleijfer S, van der Graaf WT, Touati N, Litière S, Marreaud S, Gronchi A, Kasper B


Title: A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment

Details: ESMO 2016 Congress, 10.10.2016, 13:00 – 14:00, Hall E

Authors: Ray-Coquard I, Dei Tos A, Coens C, Huizing MT, Casado A, Westermann AM, Bompas E, Earl H, Hensley ML, Negrouk A, Reed N.


Title: Gender and chemotherapy-related toxicity in colon cancer: An analysis of the PETACC-3 trial conducted by the EORTC GI-group

Details: ESMO 2016 Congress, 08.10.2016, 13:00 – 14:00, Hall E

Abstract: 2167

Authors: V. Cristina, J Mahachie, M Mauer, C Csajka, E Van Cutsem, AD Wagner

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023